ZYDUSLIFE

ZYDUS LIFESCIENCES

Large Cap BSE: 532321 NSE: ZYDUSLIFE
₹386.85
5.15 (1.35%)
As on 13 August, 2022 | 05:28

Zydus Lifesciences Share Price

Zydus Lifesciences Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Zydus Lifesciences Share Returns

  • Over 1 Month 6.45%
  • Over 3 Month 16.03%
  • Over 6 Month -1.4%
  • Over 1 Year -28.89%

Zydus Lifesciences Key Statistics

P/E Ratio 9
PEG Ratio 0.1
Market Cap Cr 39,604
Price to Book Ratio 2.1
EPS 10.7
Dividend 0.6
Relative Strength Index 68.7
Money Flow Index 87.34
MACD Signal 0.49
Average True Range 9.47

Zydus Lifesciences Investment Rating

  • Master Rating:
  • Zydus Lifesciences has an operating revenue of Rs. 15,376.30 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 19% is great, ROE of 26% is exceptional. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and around 7% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart and is trading around 1% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 50 which is a POOR score indicating inconsistency in earnings, a RS Rating of 35 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 97 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Zydus Lifesciences Financials
  • Indicator
  • Jun 2022
  • Mar 2022
  • Dec 2021
  • Sep 2021
  • Jun 2021
  • Mar 2021
  • Oper Rev Qtr Cr
  • 1,981
  • 1,919
  • 1,830
  • 2,009
  • 2,123
  • 2,019
  • Operating Expenses Qtr Cr
  • 1,437
  • 1,562
  • 1,472
  • 1,525
  • 1,506
  • 1,415
  • Operating Profit Qtr Cr
  • 544
  • 458
  • 359
  • 484
  • 618
  • 604
  • Depreciation Qtr Cr
  • 123
  • 123
  • 120
  • 119
  • 117
  • 115
  • Interest Qtr Cr
  • 41
  • 42
  • 25
  • 24
  • 44
  • 21
  • Tax Qtr Cr
  • 101
  • 100
  • 43
  • 77
  • 87
  • -23
  • Net Profit Qtr Cr
  • 332
  • 247
  • 197
  • 14
  • 400
  • 465

Zydus Lifesciences Technicals

EMA & SMA

Current Price
386.85
5.15 (1.35%)
  • Bullish Moving Average
  • ___
  • 14
  • Bearish Moving Average
  • ___
  • 2
  • 20 Day
  • 361.28
  • 50 Day
  • 359.05
  • 100 Day
  • 367.62
  • 200 Day
  • 395.19
  • 20 Day
  • 357.54
  • 50 Day
  • 357.07
  • 100 Day
  • 356.65
  • 200 Day
  • 394.71

Zydus Lifesciences Resistance and Support

PIVOT
₹377.39
Resistance
  • First Resistance
  • 387.22
  • Second Resistance
  • 392.74
  • Third Resistance
  • 402.57
Support
  • First Resistance
  • 371.87
  • Second Resistance
  • 362.04
  • Third Resistance
  • 356.52
  • RSI
  • 68.7
  • MFI
  • 87.34
  • MACD Single Line
  • 0.49
  • MACD
  • 4.2

Zydus Lifesciences Delivery and Volume

  • Period
  • NSE + BSE
    Volume Avg
  • NSE + BSE
    Delivery Volume Avg
  • NSE + BSE
    Delivery Volume %
  • Day
  • 4,961,493
  • 183,773,701
  • 37.04
  • Week
  • 2,920,660
  • 104,559,637
  • 35.8
  • 1 Month
  • 2,057,935
  • 89,067,437
  • 43.28
  • 6 Month
  • 1,484,884
  • 61,563,280
  • 41.46

Zydus Lifesciences Result Highlights

Zydus Lifesciences Synopsis

NSE-Medical-Generic Drugs

Zydus Lifesciences is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 7981.90 Cr. and Equity Capital is Rs. 102.40 Cr. for the Year ended 31/03/2022. Zydus Lifesciences Ltd. is a Public Limited Listed company incorporated on 15/05/1995 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1995PLC025878 and registration number is 025878.
  • Market Cap
  • 39,603
  • Sales
  • 7,839
  • Shares in Float
  • 25.59
  • No of funds
  • 177
  • Yield
  • 0.65
  • Book Value
  • 2.99
  • U/D Vol ratio
  • 1.4
  • LTDebt / Equity
  • 1
  • Alpha
  • -0.17
  • Beta
  • 0.89

Zydus Lifesciences

  • Owner Name
  • Jun-22
  • Mar-22
  • Dec-21
  • Sep-21
  • Promoters
  • 74.88%
  • 74.88%
  • 74.88%
  • Mutual Funds
  • 4.62%
  • 5.55%
  • 4.85%
  • Insurance Companies
  • 7.3%
  • 6.7%
  • 6.5%
  • Foreign Portfolio Investors
  • 2.86%
  • 2.53%
  • 3.79%
  • Financial Institutions/ Banks
  • 0.53%
  • 0.43%
  • Individual Investors
  • 8.02%
  • 7.81%
  • 7.4%
  • Others
  • 2.32%
  • 2%
  • 2.15%

Zydus Lifesciences Management

  • Name
  • Designation
  • Mr. Pankaj R Patel
  • Chairman
  • Dr. Sharvil P Patel
  • Managing Director
  • Mr. Ganesh N Nayak
  • Executive Director
  • Mr. Bhadresh K Shah
  • Independent Director
  • Mr. Mukesh M Patel
  • Non Executive Director
  • Mr. Nitin R Desai
  • Independent Director
  • Ms. Dharmishtaben N Raval
  • Independent Woman Director
  • Ms. Apurva S Diwanji
  • Independent Director

Zydus Lifesciences Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Zydus Lifesciences Corporate Action

  • Date
  • Purpose
  • Remarks
  • 2022-08-10
  • Quarterly Results
  • 2022-05-20
  • Audited Results, Dividend & Buy Back
  • 2022-02-03
  • Quarterly Results
  • 2021-10-29
  • Quarterly Results
  • 2021-08-11
  • Quarterly Results
  • Date
  • Purpose
  • Remarks
  • 2022-07-29
  • FINAL
  • Rs.2.50 per share(250%)Final Dividend

Zydus Lifesciences MF Shareholding

  • Name
  • Amount(cr)
  • Kotak Flexicap Fund Growth
  • 36316
  • ICICI Prudential Bluechip Fund Growth
  • 32525
  • ICICI Prudential Value Discovery Fund Growth
  • 24694
  • Parag Parikh Flexi Cap Regular Growth
  • 24595
  • Kotak Equity Arbitrage Fund Growth
  • 24543

About Company

Zydus Lifesciences Limited (Zydus) is one of India’s leading pharmaceutical companies, engaged in the formulation and marketing of pharmaceutical products. Zydus Group has a leadership position in several segments in its portfolio with brands that are market leaders in their respective categories. 

The Group has a strong presence across therapeutic segments including pain management, cardiovascular diseases, urology and anti-infectives. It also offers over-the-counter healthcare products. It sells medicines through retail pharmacies, hospitals, and clinics to customers all over India and exports to various countries worldwide. 

The Company is organized into three business verticals: Pharmaceuticals, Active Ingredients and Contract Manufacturing Services (CMS). It manufactures active ingredients for use in formulations manufactured by other pharmaceutical companies; distributes finished formulations; provides contract manufacturing services for branded drugs, and markets finished formulations under its brand names.

Business Verticals

Zydus Lifesciences has three business divisions. The largest division is pharmaceuticals, which includes oral solid dosage and injectables. The second division is hospital equipment and supplies. Finally, there is a medical education division that includes training programs for medical professionals in both rural and urban areas as well as retail stores selling over-the-counter products to consumers.  

In addition to these divisions, Zydus Lifesciences provides consulting services for companies looking to enter or expand their presence in India. These services include regulatory and market access assistance, drug registration services, strategic marketing support and distribution channel optimization.

 

Milestones

1995 - Cadila Healthcare Ltd, the flagship company of the Zydus Cadila Group, was founded.

1996 - It went public in July. They also formed a strategic alliance with Gulin Pharma of China and launched Falcigo, an anti-malarial segment, in India.

2000 - In May, the company acquired Recon Ltd's formulation business, to strengthen its position in the southern market.

2001 - Acquired German Remedies which was the largest M&A in the Indian Pharmaceutical sector at the time. The same year they formed a joint venture with US-based Onconova for collaborative research in the field of Oncogenomics.

2002 - In April, the company acquired Banyan Chemicals, a Vadodara-based company registered with the US Food and Drug Administration.

2003 - Zydus Group decided to merge German Remedies Ltd and Recon Healthcare Ltd with Cadila Healthcare Ltd

2004 - In November, the company formed a strategic alliance with the Zambon Group in Italy to explore new opportunities in contract manufacturing. The same year, the company signed a long-term strategic agreement with Boehringer Ingelheim India Ltd, a wholly-owned subsidiary of Boehringer Ingelheim (BI), to manufacture and market BI's products in India.

2005 - The company formed a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a Tyco Healthcare business unit, to market the company's product under a joint label. In the same year, the company formed a 50:50 joint venture with Australia's Mayne Pharma to produce generic injectable cytotoxic (anti-cancer) medicines as well as active pharmaceutical ingredients (API) for global markets.

2005-06 - During this fiscal year, the company formed a 50:50 joint venture with one of India's leading biotech companies, Bharat Serums and Vaccines Ltd (BSV), to develop, manufacture, and market a non-infringing and proprietary Novel Drug Delivery System (NDDS) of an approved anticancer product for global markets.

2006-07 - During this fiscal year, the company entered into a share purchase agreement to acquire a 97.95 per cent stake in Liva Healthcare Ltd, which manufactures and markets Formulations. They also built a brand-new green field facility for Solid Oral Dosage. They also built a Lyophilisation facility at the Moraiya plant with an annual capacity of 7.5 million dosages to serve both the Indian and international markets.

2007-08 - During this fiscal year, the company restructured its formulation division, Alidac, and launched two new subdivisions, Corza and Fortiza.
 

Zydus Lifesciences FAQs

What is Share Price of Zydus Lifesciences ?

Zydus Lifesciences share price is ₹386 As on 13 August, 2022 | 05:14

What is the Market Cap of Zydus Lifesciences ?

The Market Cap of Zydus Lifesciences is ₹39603.5 Cr As on 13 August, 2022 | 05:14

What is the P/E ratio of Zydus Lifesciences ?

The P/E ratio of Zydus Lifesciences is 9 As on 13 August, 2022 | 05:14

What is the PB ratio of Zydus Lifesciences ?

The PB ratio of Zydus Lifesciences is 2.1 As on 13 August, 2022 | 05:14

What were the company's most recent reported sales and net income?

Zydus Lifesciences Ltd. recorded a net income of INR 15,265.20  crores in FY22

What is the future of the company's shares?

Zydus Lifesciences Ltd. stock is a good option for long-term investment since the shares are ripe for buying right now.

How to buy shares of Zydus Lifesciences Ltd.?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

Q1FY23